(Nature) – It is 20 years since induced pluripotent stem cells shook biomedicine. Public trust must be retained now that clinical trials are well under way.

Earlier this year, the first such therapies — one for Parkinson’s disease and the other for heart failure — received conditional approval in Japan. Clinical trials of iPS-cell therapies are under way around the world.

The stem-cell field now stands at a turning point. As more therapies are rolled out, the goal of researchers, companies and regulators must be to ensure that these treatments are developed responsibly, and that they will be available to all who need them. (Read More)